Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Multiple Myeloma

ClinicalTrials.gov lists 3,663 trials for Multiple Myeloma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 138.

MeSH D009101 Neoplasms Neoplasm C04 C14 C15 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 829 Phase 1/2 Phase 1/2 450 Phase 2 Phase 2 1,108 Phase 2/3 Phase 2/3 30 Phase 3 Phase 3 347 Phase 4 Phase 4 52 Not applicable Not applicable 334 Observational Observational 480 Phase 1 Phase 1 829 Phase 1/2 Phase 1/2 450 Phase 2 Phase 2 1,108 Phase 2/3 Phase 2/3 30 Phase 3 Phase 3 347 Phase 4 Phase 4 52 Not applicable Not applicable 334 Observational Observational 480

Trials per phase (log scale)

2 more sections with rows

3,652 of the 3,663 trials are tagged with Multiple Myeloma itself; the rest are tagged with a narrower condition beneath it.

Get the Multiple Myeloma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Multiple Myeloma trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 11 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 192

1991: 1 trials (Phase 2 1) 1992: 2 trials (Phase 2 2) 1993: 5 trials (Observational 1, Phase 3 1, Phase 2 3) 1994: 5 trials (Phase 3 3, Phase 2 2) 1995: 9 trials (Phase 3 3, Phase 2 4, Phase 1/2 1, Phase 1 1) 1996: 12 trials (Observational 1, Phase 3 4, Phase 2 6, Phase 1 1) 1997: 26 trials (Not applicable 3, Phase 3 5, Phase 2 12, Phase 1/2 2, Phase 1 4) 1998: 39 trials (Not applicable 2, Phase 4 1, Phase 3 6, Phase 2 22, Phase 1/2 1, Phase 1 7) 1999: 40 trials (Not applicable 4, Phase 3 8, Phase 2 16, Phase 1/2 4, Phase 1 8) 2000: 53 trials (Observational 2, Not applicable 5, Phase 3 14, Phase 2/3 1, Phase 2 18, Phase 1/2 8, Phase 1 5) 2001: 46 trials (Observational 3, Not applicable 5, Phase 4 1, Phase 3 4, Phase 2/3 2, Phase 2 18, Phase 1/2 6, Phase 1 7) 2002: 60 trials (Observational 3, Not applicable 4, Phase 3 10, Phase 2/3 1, Phase 2 27, Phase 1/2 7, Phase 1 8) 2003: 62 trials (Observational 2, Not applicable 8, Phase 4 1, Phase 3 16, Phase 2/3 1, Phase 2 13, Phase 1/2 7, Phase 1 14) 2004: 83 trials (Observational 5, Not applicable 7, Phase 4 3, Phase 3 8, Phase 2/3 2, Phase 2 35, Phase 1/2 11, Phase 1 12) 2005: 100 trials (Observational 5, Not applicable 8, Phase 3 12, Phase 2 43, Phase 1/2 12, Phase 1 20) 2006: 113 trials (Observational 13, Not applicable 6, Phase 4 2, Phase 3 18, Phase 2 41, Phase 1/2 16, Phase 1 17) 2007: 107 trials (Other 1, Observational 7, Not applicable 6, Phase 4 2, Phase 3 9, Phase 2/3 1, Phase 2 44, Phase 1/2 14, Phase 1 23) 2008: 140 trials (Observational 17, Not applicable 6, Phase 3 16, Phase 2/3 1, Phase 2 50, Phase 1/2 13, Phase 1 37) 2009: 112 trials (Other 2, Observational 14, Not applicable 6, Phase 3 16, Phase 2/3 4, Phase 2 31, Phase 1/2 17, Phase 1 22) 2010: 136 trials (Observational 18, Not applicable 9, Phase 4 3, Phase 3 11, Phase 2 50, Phase 1/2 24, Phase 1 21) 2011: 116 trials (Observational 15, Not applicable 8, Phase 4 1, Phase 3 12, Phase 2 37, Phase 1/2 20, Phase 1 23) 2012: 133 trials (Observational 13, Not applicable 7, Phase 4 1, Phase 3 7, Phase 2 53, Phase 1/2 19, Phase 1 33) 2013: 106 trials (Observational 15, Not applicable 9, Phase 4 1, Phase 3 8, Phase 2/3 1, Phase 2 31, Phase 1/2 19, Phase 1 22) 2014: 133 trials (Observational 14, Not applicable 9, Phase 4 2, Phase 3 9, Phase 2/3 1, Phase 2 39, Phase 1/2 17, Phase 1 42) 2015: 138 trials (Observational 18, Not applicable 6, Phase 4 2, Phase 3 12, Phase 2/3 1, Phase 2 51, Phase 1/2 14, Phase 1 34) 2016: 129 trials (Observational 20, Not applicable 8, Phase 4 1, Phase 3 8, Phase 2 51, Phase 1/2 16, Phase 1 25) 2017: 145 trials (Observational 25, Not applicable 6, Phase 4 1, Phase 3 13, Phase 2/3 1, Phase 2 41, Phase 1/2 18, Phase 1 40) 2018: 146 trials (Observational 20, Not applicable 10, Phase 4 2, Phase 3 7, Phase 2/3 1, Phase 2 52, Phase 1/2 16, Phase 1 38) 2019: 168 trials (Observational 23, Not applicable 11, Phase 4 5, Phase 3 13, Phase 2/3 1, Phase 2 42, Phase 1/2 28, Phase 1 45) 2020: 141 trials (Observational 30, Not applicable 22, Phase 4 1, Phase 3 11, Phase 2/3 1, Phase 2 28, Phase 1/2 9, Phase 1 39) 2021: 192 trials (Observational 30, Not applicable 19, Phase 4 1, Phase 3 11, Phase 2 54, Phase 1/2 23, Phase 1 54) 2022: 192 trials (Observational 39, Not applicable 26, Phase 4 6, Phase 3 13, Phase 2 39, Phase 1/2 21, Phase 1 48) 2023: 191 trials (Observational 38, Not applicable 30, Phase 4 2, Phase 3 11, Phase 2/3 2, Phase 2 40, Phase 1/2 31, Phase 1 37) 2024: 169 trials (Observational 31, Not applicable 24, Phase 4 3, Phase 3 15, Phase 2 30, Phase 1/2 17, Phase 1 49) 2025: 166 trials (Observational 27, Not applicable 31, Phase 4 4, Phase 3 11, Phase 2/3 2, Phase 2 38, Phase 1/2 17, Phase 1 36)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 186
2025 166
2024 169
2023 191
2022 192
2021 192
2020 141
2019 168
2018 146
2017 145

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 200 trials starting in 2026 and about 190 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 466 trials still running at the 2026-10-09 snapshot; registered median of 39 months across 2,257 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Multiple Myeloma trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 829
Phase 1/2 450
Phase 2 1,108
Phase 2/3 30
Phase 3 347
Phase 4 52
Not applicable 334
Observational 480
Expanded access 32
Unknown 1

How many Multiple Myeloma trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 145
Recruiting 515
Enrolling by invitation 9
Active, not recruiting 293
Available 6

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Multiple Myeloma trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 138
Celgene 92
Janssen Research & Development, LLC 63
Amgen 42
GlaxoSmithKline 40

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Multiple Myeloma? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 299
Melphalan 221
POMALIDOMIDE 181
THALIDOMIDE 98
IXAZOMIB 76

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 704
Bortezomib SC 392
X: Lenalidomide 380
Daratumumab SC 197
SQ Fludarabine 196

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Multiple Myeloma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 4,381 284
Pyrexia 1,466 205
Thrombocytopenia 1,315 167
Sepsis 1,162 278
Febrile neutropenia 1,104 207

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Multiple Myeloma? (2,173)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort. Cancer 2026 Yes
The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma. Blood 2026 Yes
Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy. Blood 2026 Yes
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone. Blood 2026 Yes
Long-term follow-up of zevor-cel in patients with relapsed/refractory multiple myeloma. Blood advances 2026 Yes

Showing 5 of 2,173 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (27)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Multiple myeloma Annual incidence 1-9 / 100 000 United States US Exact
Multiple myeloma Annual incidence 1-9 / 100 000 United States US Exact
Multiple myeloma Prevalence at birth 1-9 / 100 000 United States US Unspecified
Multiple myeloma Prevalence at birth 1-9 / 100 000 United States US Exact
Multiple myeloma Annual incidence 1-9 / 100 000 United States US Unspecified

Showing 5 of 27 prevalence observations.

Start your 14-day trial Email me all 27 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Multiple myeloma 29073 Exact Orphadata Science knowledge files, Product 1
Multiple myeloma 29073 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages